Beneficial effects of weight loss on plasma apolipoproteins in postmenopausal women.
A total of 39 postmenopausal women 40-70 years of age and undergoing hormone replacement therapy participated in a 6-month weight reduction program, which consisted of a low calorie diet (5040 KJ/day) and phentermine hydrochloride therapy. Subjects had an average body mass index of 35.95+/-5.32 kg/m(2) and 42.20+/-11.0 kg of total fat. Body mass index, plasma lipids, total and trunk fat, and plasma apoproteins were measured at baseline and after 3 and 6 months of the weight reduction program. Subjects experienced an overall 10% weight loss during the treatment period (P<0.001). Plasma LDL cholesterol and triglycerides were reduced by 18% and 15% (P<0.01) respectively, whereas HDL cholesterol was increased by 9% (P<0.01) over the 6-month period. Plasma apoproteins were significantly affected by weight loss. Plasma apolipoprotein (apo) B concentrations were reduced 6.5% (P<0.01), and apo C-III and apo E were reduced by 9% over 6 months (P<0.01). The observed decreases in plasma apo B were significantly correlated with the observed changes in plasma cholesterol (r=0.356, P<0.01) over 3 months. In addition, changes in plasma triglycerides were correlated with changes in both apo C-III (r=0.436) and apo E (r=0.354) over 6 months. These results suggest that weight loss may have multifactorial effects on lipoprotein metabolism, resulting in better plasma lipid and apoprotein profiles.
Fernandez
Maria Luz
ML
Department of Nutritional Sciences, University of Connecticut, 3624 Horsebarn Road Ext., Storrs, CT 06268, USA. maria-luz.fernandez@uconn.edu
Metghalchi
Shiva
S
Vega-López
Sonia
S
Conde-Knape
Karin
K
Lohman
Timothy G
TG
Cordero-Macintyre
Zaida R
ZR
D000328:Adult; D000368:Aged; D053305:Apolipoprotein C-III; D001053:Apolipoproteins / Q000097:blood*; D001055:Apolipoproteins B / Q000097:blood; D001056:Apolipoproteins C / Q000097:blood; D001057:Apolipoproteins E / Q000097:blood; D001067:Appetite Depressants / Q000627:therapeutic use; D015992:Body Mass Index; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D004038:Diet, Reducing; D002149:Energy Intake; D015914:Estrogen Replacement Therapy; D005260:Female; D006801:Humans; D008875:Middle Aged; D010645:Phentermine / Q000627:therapeutic use; D017698:Postmenopause / Q000097:blood*; D014280:Triglycerides / Q000097:blood; D015431:Weight Loss
D053305:Apolipoprotein C-III; D001053:Apolipoproteins; D001055:Apolipoproteins B; D001056:Apolipoproteins C; D001057:Apolipoproteins E; D001067:Appetite Depressants; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D014280:Triglycerides; D010645:Phentermine